SCHEMBL14810792

SCHEMBL14810792

CCC(C)NCC1CCCCC1

nearest known ligand 0.46

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
HTT P42858 1/20 0.46
EPHX1 P07099 4/20 0.42
SIGMAR1 Q99720 1/20 0.42
ADH1B P00325 1/20 0.39
ADH1C P00326 1/20 0.39
ADH1A P07327 1/20 0.39
ADH4 P08319 1/20 0.39
ADH7 P40394 1/20 0.39
SHBG P04278 1/20 0.38
CYP1A2 P05177 1/20 0.37
HTR2A P28223 1/20 0.36
HTR2C P28335 1/20 0.36
HTR2B P41595 1/20 0.36
EPHX2 P34913 1/20 0.34
CA12 O43570 1/20 0.33
CA1 P00915 1/20 0.33
CA2 P00918 1/20 0.33
MMP1 P03956 1/20 0.33
MMP2 P08253 1/20 0.33
MMP3 P08254 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL172619 1.00 HTT (0.46) HTTEPHX1SIGMAR1ADH1BADH1C
SCHEMBL28057484 0.89
SCHEMBL891398 0.89 SIGMAR1 (0.50) HTTEPHX1SIGMAR1
SCHEMBL25086700 0.85 HTT (0.38) HTTEPHX1SIGMAR1ADH1BADH1C
SCHEMBL26456057 0.85 HTT (0.38) HTTEPHX1SIGMAR1ADH1BADH1C
SCHEMBL23462691 0.82 HTT (0.36) HTTEPHX1SIGMAR1
SCHEMBL104714 0.81 ADH1B (0.44) HTTEPHX1SIGMAR1ADH1BADH1C
SCHEMBL22899465 0.81 ADH1B (0.44) HTTEPHX1SIGMAR1ADH1BADH1C
SCHEMBL14176594 0.81 ADH1B (0.44) HTTEPHX1SIGMAR1ADH1BADH1C
SCHEMBL13995960 0.81 HTT (0.45) HTTEPHX1SIGMAR1ADH1BADH1C

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-10550073-B2 Benzamide derivative CSPC ZHONGQI PHARMACEUTICAL TECHNOLOGY (SHIJIAZHUANG) CO., LTD. (CN) 2020-02-04 US disclosed
WO-2019186164-A1 FACTOR XIIA INHIBITORS UNIVERSITY OF LEEDS (GB) 2019-10-03 WO disclosed
US-20170044100-A1 INHIBITORS OF DRUG-RESISTANT MYCOBACTERIUM TUBERCULOSIS UNIV JOHNS HOPKINS (US) 2017-02-16 US disclosed
EP-2758445-A2 EPOXY-FUNCTIONAL RESIN COMPOSITIONS Dow Global Technologies LLC (US) 2014-07-30 EP disclosed
WO-2013043363-A2 EPOXY-FUNCTIONAL RESIN COMPOSITIONS DOW GLOBAL TECHNOLOGIES LLC (US) 2013-03-28 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20170044100-A1 INHIBITORS OF DRUG-RESISTANT MYCOBACTERIUM TUBERCULOSIS IDO2, IDO1, INMT HTT 3977/4885EPHX1 2812/4885SIGMAR1 4133/4885
US-10550073-B2 Benzamide derivative CYP3A5, ABCB1, CYP2D6 HTT 2092/4885EPHX1 1725/4885SIGMAR1 211/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.